Advertisement

BMC Research Notes

, 12:561 | Cite as

Safety and tolerance of lymph node biopsies from chronic HIV-1 volunteers in rural Tanzania

  • Catherine Gerald Mkindi
  • Elias Antony Marandu
  • Ngisi Masawa
  • Farida Bani
  • Amina Nyuri
  • Theonestina Byakuzana
  • Thomas Klimkait
  • Song Ding
  • Giuseppe Pantaleo
  • Manuel Battegay
  • Nina Orlova-Fink
  • Maja Weisser-Rohacek
  • Claudia DaubenbergerEmail author
Open Access
Research note

Abstract

Objective

HIV-1 rapidly establishes a persistent infection that can be contained under life-long antiretroviral therapy (ART) but not cured. One major viral reservoir is the peripheral lymph node (LN) follicles. Studying the impact of novel HIV-1 treatment and vaccination approaches on cells residing in germinal centers is essential for rapid progress towards HIV-1 prevention and cure.

Results

We enrolled 9 asymptomatic adult volunteers with a newly diagnosed HIV-1 infection and CD4 T cell counts ≥ 350/ml. The patients underwent venous blood collection and inguinal lymph node excision surgery in parallel. Mononuclear cells were extracted from blood and tissues simultaneously. Participants were followed up regularly for 2 weeks until complete healing of the surgical wounds. All participants completed the lymph node excision surgery without clinical complications. Among the 9 volunteers, one elite controller was identified. The number of mononuclear cells recovered from lymph nodes ranged from 68 to 206 million and correlated positively with lymph node size. This is the first study to show that lymph node biopsy is a safe procedure and can be undertaken with local experts in rural settings. It provides a foundation for detailed immune response investigations during future clinical trials.

Keywords

Lymph node biopsy KIULARCO cohort Tanzania HIV-1 Chronic Elite controller 

Abbreviations

ART

antiretroviral therapy

bnABs

broadly neutralizing antibodies

CDCI

Chronic Diseases Clinic of Ifakara

DMSO

dimethyl sulfoxide

FCS

fetal calf serum

GC

germinal center

HIV-1

human immunodeficiency virus type 1

KIULARCO

Kilombero and Ulanga Antiretroviral Cohort

LN

lymph node

LNMC

lymph node mononuclear cells

PLWHIV

people living with HIV

RDT

rapid diagnostic test

SFRH

Saint Francis Referral Hospital, Ifakara, Tanzania

SSA

sub-Saharan Africa

Tfh

follicular B helper T cells

Tfr

follicular regulatory T cells

UNAIDS

Joint United Nations Programme on HIV and AIDS

WHO

World Health Organization

Introduction

Human immunodeficiency virus type 1 (HIV-1) has become one of the most serious global health challenges, despite intensive research over the last 30 years. In 2017, of the estimated 36.9 million people living with HIV (PLWHIV) worldwide, 19.6 million resided in eastern and southern Africa [1]. The UNAIDS goals of 90-90-90 by 2020 (90% diagnosed, 90% treated, 90% virally suppressed), are not yet met in Tanzania: 66% of those diagnosed with HIV-1 are on ART and 48% of these have suppressed viremia, while no numbers are published for the first 90 [1].

Most current vaccines provide protection by generating antibodies that neutralize pathogen entry or spread [2]. Numerous efforts to elicit broadly neutralizing antibodies (bnAbs) against HIV in experimental animals and humans have been unsuccessful [3]. However, many HIV-1 infected patients naturally develop bnAbs that can effectively neutralize a broad range of HIV-1 variants and suppress viremia [4]. The development of such potent antibodies usually takes several years and is poorly understood as selection takes place in the germinal centers (GC) located in secondary lymphoid organs, where B cells closely interact with T-follicular helper cells (Tfh), T follicular regulatory (Tfr) cells, macrophages and follicular dendritic cells [5, 6]. Studying these cell populations and their interactions is of a great importance but has so far been very limited, since access to those tissues is challenging. In humans, several markers for Tfh circulating in peripheral blood have been established, including ICOS, PD1 and CXCR5 expression [7], enabling the investigation of vaccine-induced responses against vaccination in peripheral blood [8, 9]. However, the functional and biological relationship between circulating Tfh and cells residing in secondary lymphoid organs is unclear and requires further investigation [10].

The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) is a single-site, open and ongoing prospective cohort of HIV-1 patients established in 2005 at the Chronic Diseases Clinic of Ifakara (CDCI), located at the Saint Francis Referral Hospital (SFRH) in Ifakara, Tanzania [11]. One of the objectives of KIULARCO is to provide a platform for clinical studies on improving HIV-1 care and treatment [12]. Here, as a proof of concept, we performed a lymph node excision study from asymptomatic, chronically HIV-1-infected volunteers in this rural setting in Tanzania.

Main text

Results

Nine ART-naïve, HIV-1-positive volunteers were enrolled into the study between June and August 2018. Volunteers reported that they came to SFRH for reasons other than acute sickness or suspicion of HIV infection (Table 1). At enrolment, all participants were clinically healthy, with no fever, chills or headache recorded. The female-to-male ratio was 3:1 and the average age of the volunteers was 34 years (range 23–55 years). CD4 T-cell counts were on average 698 cells/ml (range 434–1302) and the HIV-1 viral loads, assessed at the time of diagnosis, measured on average 35,500 copies/ml (range < 50 to 133,200).
Table 1

Demographic characteristics and clinical data of the volunteers

 

Volunteer ID

V1

V2

V3

V4

V5

V6

V7

V8

V9

Age

40

55

42

29

23

23

37

26

30

Gender

F

F

F

F

F

M

F

M

M

BMI

18.7

22.2

28.4

24.9

21.3

23

31.6

18.8

29.7

Marital status

Divorced

Divorced

Divorced

Single

Single

Married

Married

Single

Single

CD4 count (cells/ml)

538

662

1302

846

679

594

434

665

566

HIV-1 RNA (copies/ml)

1670

68,300

< 50

8150

725

113,200

72,200

53,900

1210

Hb (g/l)

13.9

12.0

12.1

12.7

10.2

14.1

13.8

15.0

13.7

Syphilis

Negative

Negative

Negative

Negative

Negative

Negative

Negative

Negative

Negative

Hepatitis B

Negative

Negative

Negative

Negative

Negative

Negative

Negative

Negative

Negative

Clinical presentation

Healthy

Healthy

Healthy

Healthy

Healthy

Healthy

Healthy

Healthy

Healthy

Reason for HIV-1 testing

Ear injury

History of herpes zoster lesions

Chronic body malaise

Marital requirement

Employer request

Wife’s antenatal clinic visit

Referred

Voluntary Testing

Voluntary

Testing

For all participants the duration of infection is unknown, but given their asymptomatic conditions, relatively moderate viral loads and healthy CD4 T-cell counts, it is safe to assume that the participants have a chronic HIV-1 infection.

Interestingly, one of the volunteers (V3), who had a positive diagnosis for HIV-1 with two different RDTs, showed undetectable HIV-1 viral load (< 50 copies/ml) and high CD4 T-cell count (1302 cells/ml), the highest in this cohort. HIV-1, but not HIV-2, infection for this volunteer was confirmed by additional testing with a line immunoassay (Fig. 1) suggesting a rare elite controller phenotype.
Fig. 1

Detection of HIV-1 specific antibodies in participant V3 by a line immunoassay (HIV-1 detection bands indicated in red, HIV-2 in black)

Lymph node biopsies were successfully conducted from all 9 volunteers and the sizes of extracted nodes ranged from 3 to 15 mm (Fig. 2a). After extraction, LMNC were immediately isolated in the closely located laboratory. Viability of LMNC ranged from 97 to 99% and the count of recovered LMNC ranged from 68 to 206 million. The LNMC yield correlated positively with the lymph node size (Fig. 2b), supporting strongly that healthy secondary lymphoid organs were extracted. Cell samples were aliquoted and stored within an hour after surgical excision. Except for two volunteers, who developed self-resolving hyperaemia surrounding the incision site, none of the volunteers experienced any complications in relation to the lymph node biopsy. The incisons healed as expected and all volunteers were discharged from attending regular hospital visits by day 14 the latest. Volunteers started HIV-1 treatment on the day of enrolment in KIULARCO, as recommended by the national treatment guidelines of Tanzania.
Fig. 2

a Pictures of lymph node biopsies taken from volunteers. b Positive correlation between LN size and cell yield

Discussion

Biopsies of inguinal lymph nodes together with a paired venous blood sample were collected from nine HIV-1 infected patients in rural settings in Tanzania. To our knowledge, this is the first study of this kind in Tanzania. We demonstrate that this procedure is safe and well-tolerated with minimal adverse events that can resolve within 14 days after surgery. The short recruitment period of volunteers into the study demonstrates that the KIULARCO cohort serves as an elegant platform for clinical HIV research. HIV-1 is not curable using the currently available treatment approaches, resulting in a growing number of PLWHIV who need to adhere to life-long ART treatment [13]. One of the common compartments for viral persistence is Tfh cells, making them an important target for experimental approaches to a cure for HIV [14].

A recent report by D´Souza provided an excellent overview of the value of lymph node biopsies in the context of experimental HIV-1 vaccine trials [15]. Lymph node biopsies have been shown to be safe in HIV-1-positive volunteers, with up to 4 lymph nodes able to be consecutively removed from participants during a HIV-1 vaccine study in Thailand [16]. The bulk of information generated about GC development and responses has been derived from studies on secondary lymphoid tissues in mice. It is assumed that heterogeneity of GC Tfh cells impacts antibody isotypes produced by plasma blasts and long-lived memory B cells [17]. In humans, GC Tfh are a functionally and phenotypically heterogeneous population based on the expression of PD1, CXCR3, CCR6, CCR7 and ICOS markers [18]. People living in SSA are exposed to co-infections such as malaria and helminths, which potentially impact GC Tfh cell function and cytokine secretion [19]. Studying the environmental drivers of the functional heterogeneity of GC Tfh in a rural African population will provide essential information on HIV pathogenesis, treatment as well as routine and experimental vaccine monitoring in a population highly affected by the HIV epidemic [20].

Conclusions

Inguinal lymph node excisions can be safely performed by local experts in a rural sub-Saharan African setting, so long as precautions such as infection prevention are in place and followed carefully. Thus, the procedure is a feasible practice in the framework of monitoring novel intervention studies in HIV-1 clinical research. The KIULARCO cohort provides a valuable platform for clinical research, supporting the evaluation of novel interventions in a population that is highly affected by HIV-1 but rather neglected in relation of testing novel interventions.

Methods

Study site

This study was conducted in the rural communities of Morogoro region in Tanzania, involving two districts: Kilombero and Ulanga. The Chronic Diseases Clinic of Ifakara (CDCI) located at the St Francis Referral Hospital (SFRH) runs an antiretroviral cohort (Kilombero and Ulanga Antiretroviral Cohort, KIULARCO). KIULARCO includes all HIV-1-positive patients enrolled in care. SFRH has in- and outpatient services and specialized clinics including theatres with facilities needed for patient recruitment and lymph node extraction. The Ifakara Health Institute runs an advanced laboratory infrastructure, supporting immunological and virological sample processing and long-term storage.

Volunteer recruitment and diagnostics

All patients seen for any health condition at SFRH are offered an HIV-1 test following the national strategic plan [11]. In 2014, SFRH adopted the WHO strategy for universal HIV-1 testing for all visitors, regardless of health condition. Routine testing for HIV-1 is done by a rapid diagnostic test (RDT) (SD Bioline), confirmed by a secondary RDT (Unigold) where necessary. HIV-1 viral RNA plasma loads are quantified by using GenXpert with a detection limit of 50 copies/ml. For confirmation of HIV infection and differentiation between HIV-1 and HIV-2, the line immunoassay, INNO-LIA HIV I/II Score (Fujirebio, Ghent, Belgium) (Inno-Lia), had been used in one volunteer (V3), whose viral load was below the limit of detection by GenXpert.

HIV-1 positive volunteers were eligible for enrolment dependent on meeting the following criteria: between 18 and 55 years of age, newly diagnosed (ART-naïve), CD4 T-cell count above 350 cells/ml, no active co-morbidities, negative for hepatitis B (HBsAg), Syphilis and malaria. Volunteers were informed about study procedures and consented to paired blood and lymph node removal. All volunteers were recruited into the KIULARCO on the same day, after consenting, and provided with ART treatment.

Blood sample collection and PBMC isolation

Whole blood was collected from all participants on the day of the LN biopsies. Plasma and serum samples were prepared following established procedures [12] and stored at − 80 °C. PBMCs were isolated by density gradient centrifugation using Ficoll-Hypaque and stored in Fetal calf serum (FCS) with 10% DMSO in liquid nitrogen until further analysis.

Lymph node extraction and cell isolation

A surgical procedure to excise a single inguinal LN from each volunteer was performed aseptically at the SFRH theatre following local anaesthesia, 2% lidocaine 5 ml. An incision of 1–2 cm in length was made at the right or left inguinal area. LNs were immediately preserved in R10 medium (RPMI with 1% Penicillin/Streptomycin and 10% FCS) for transport and processing. The incisions were sutured and patients were prescribed analgesics before being discharged. Patients were asked to come for three visits within 14 days of surgery for postoperative wound care. Lymph node mononuclear cells (LNMC) were extracted in R10 medium by mechanical disruption of the tissue causing cell release, followed by filtering with a 100un filter. Cell counts and viability were determined by microscopy using 0.4% trypan blue solution staining.

Limitations

The study was designed as a pilot study, therefore included a limited number of the participants.

Notes

Acknowledgements

We acknowledge the CDCI clinic for incorporating our study protocol in their cohort and the participation of all study volunteers. We are thankful to Dr. Alessandra Noto, who offered training on LNMC isolation from lymph node biopsy and Prof. Jean-Marc Corpataux for training on inguinal lymph node surgical excision. Both are with the University Hospital, Lausanne, Switzerland.

Authors’ contributions

CAD and MWR were the principal investigators and conceived the proposal idea with the help of EAM, GP and SD. CGM performed sample collection, laboratory preparation and analyses, contributed to the conception of the study and the manuscript writing with the help of CAD, MWR, NOF, TK and MB. EAM performed all surgical procedures and helped with proposal development. NM and FB implemented patient recruitment, care and study design. AN and TB assisted in lab work and proposal design. All authors read and approved the final manuscript.

Funding

The Swiss Tropical and Public Health Institute (Basel, Switzerland) provided financial support to the study. The funder had no role in study design, data collection, analysis and interpretation, decision to publish, or preparation of the manuscript.

Ethics approval and consent to participate

This study was conducted after the approval of the Ifakara Health Institute Institutional Review Board (IHI/IRB Certificate #029-2016) and the National Medical Review Board of Tanzania (NIMR/HQ/R.8a/Vol.IX/2374). Permission to conduct the study was also obtained from the Commission Cantonale D’éthique De La Recherche Sur L’être Humain (Cer-Vd) in Switzerland. Samples were collected after written consent, which included a brief description about the procedure and the importance of the study, was obtained from all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

  1. 1.
    UNAIDS: Global AIDS update 2018. https://www.unaids.org/en/20180718_GR2018. Accessed 10 June 2019.
  2. 2.
    Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055–65.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Escolano A, Dosenovic P, Nussenzweig MC. Progress toward active or passive HIV-1 vaccination. J Exp Med. 2017;214(1):3–16.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. Aids. 2014;28(2):163–9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2012;30:429–57.CrossRefGoogle Scholar
  6. 6.
    Vaccari M, Franchini G. T cell subsets in the germinal center: lessons from the macaque model. Front Immunol. 2018;9:348.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med. 2000;192(11):1553–62.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Bentebibel SE, Lopez S, Obermoser G, Schmitt N, Mueller C, Harrod C, et al. Induction of ICOS + CXCR1 + CXCR1 + TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med. 2013;5(176):176ra32.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Heit A, Schmitz F, Gerdts S, Flach B, Moore MS, Perkins JA, et al. Vaccination establishes clonal relatives of germinal center T cells in the blood of humans. J Exp Med. 2017;214(7):2139–52.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Linterman MA, Hill DL. Can follicular helper T cells be targeted to improve vaccine efficacy? F1000Research. 2016.  https://doi.org/10.12688/f1000research.7388.1.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Letang E, Kalinjuma AV, Glass TR, Gamell A, Mapesi H, Sikalengo GR, et al. Cohort profile: the Kilombero and Ulanga antiretroviral cohort (KIULARCO)—a prospective HIV cohort in rural Tanzania. Swiss Med Weekly. 2017;147:w14485.Google Scholar
  12. 12.
    Steiner-Monard V, Kamaka K, Karoui O, Roethlisberger S, Audran R, Daubenberger C, et al. The candidate blood-stage malaria vaccine P27A induces a robust humoral response in a fast track to the field phase 1 trial in exposed and nonexposed volunteers. Clin Infect Dis. 2019;68(3):466–74.CrossRefPubMedGoogle Scholar
  13. 13.
    Reeves DB, Duke ER, Wagner TA, Palmer SE, Spivak AM, Schiffer JT. A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation. Nat Commun. 2018;9(1):4811.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Banga R, Procopio FA, Noto A, Pollakis G, Cavassini M, Ohmiti K, et al. PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat Med. 2016;22(7):754–61.CrossRefPubMedGoogle Scholar
  15. 15.
    Patricia D’Souza M, Allen MA, Baumblatt JAG, Boggiano C, Crotty S, Grady C, et al. Innovative approaches to track lymph node germinal center responses to evaluate development of broadly neutralizing antibodies in human HIV vaccine trials. Vaccine. 2018;36(38):5671–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Chintanaphol M, Sacdalan C, Chottanapund S, Pinyakorn S, Buranapraditkun S, Crowell TA, et al. Brief report: safety and tolerability of inguinal lymph node biopsy in individuals with acute HIV infection in Thailand. J Acquir Immune Defic Syndr. 2018;79(2):244–8.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Reinhardt RL, Liang HE, Locksley RM. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol. 2009;10(4):385–93.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G, et al. Human blood CXCR1(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011;34(1):108–21.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Obeng-Adjei N, Portugal S, Tran TM, Yazew TB, Skinner J, Li S, et al. Circulating Th1-Cell-type Tfh cells that exhibit impaired b cell help are preferentially activated during acute malaria in children. Cell Rep. 2015;13(2):425–39.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Moysi E, Pallikkuth S, De Armas LR, Gonzalez LE, Ambrozak D, George V, et al. Altered immune cell follicular dynamics in HIV infection following influenza vaccination. J Clin Invest. 2018;128(7):3171–85.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Catherine Gerald Mkindi
    • 1
    • 2
    • 3
  • Elias Antony Marandu
    • 5
  • Ngisi Masawa
    • 3
  • Farida Bani
    • 3
  • Amina Nyuri
    • 3
  • Theonestina Byakuzana
    • 3
  • Thomas Klimkait
    • 2
  • Song Ding
    • 6
  • Giuseppe Pantaleo
    • 7
    • 8
  • Manuel Battegay
    • 4
  • Nina Orlova-Fink
    • 1
    • 3
  • Maja Weisser-Rohacek
    • 1
    • 3
    • 4
  • Claudia Daubenberger
    • 1
    • 3
    Email author
  1. 1.Department of Medical Parasitology and Infection Biology, Clinical ImmunologySwiss Tropical and Public Health InstituteBaselSwitzerland
  2. 2.University of BaselBaselSwitzerland
  3. 3.Ifakara Health InstituteBagamoyoTanzania
  4. 4.Division of Infectious Diseases and Hospital EpidemiologyUniversity Hospital BaselBaselSwitzerland
  5. 5.St Francis Referral HospitalIfakaraTanzania
  6. 6.EuroVacc FoundationAmsterdamThe Netherlands
  7. 7.Service of Immunology and AllergyLausanne University HospitalLausanneSwitzerland
  8. 8.Swiss Vaccine Research InstituteLausanneSwitzerland

Personalised recommendations